Get the Stockscreener App
46.79
5.05%
2.25
Pulse Biosciences Inc stock is traded at $46.79, with a volume of 576.64K.
It is up +5.05% in the last 24 hours and up +63.15% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$44.54
Open:
$44.5
24h Volume:
576.64K
Relative Volume:
1.50
Market Cap:
$3.34B
Revenue:
$751.00K
Net Income/Loss:
$-74.57M
P/E Ratio:
-42.42
EPS:
-1.1031
Net Cash Flow:
$-55.52M
1W Performance:
+12.72%
1M Performance:
+63.15%
6M Performance:
+97.68%
1Y Performance:
+189.54%
1-Day Range:
$42.70
$46.99
1-Week Range:
$41.00
$46.99
52-Week Range:
$12.56
$46.99
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
46.79 | 3.18B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
390.33 | 139.37B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
182.09 | 49.96B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.49 | 35.89B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
220.37 | 32.38B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
34.88 | 31.36B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Needham & Company LLC Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE) - MarketBeat
PLSE Initiates Coverage On by Needham -- Price Target Announced at $58.00 - GuruFocus
Needham initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Canada
Needham Initiates Pulse Biosciences at Buy With $58 Price Target - marketscreener.com
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed? - simplywall.st
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns - finance.yahoo.com
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform - marketbeat.com
(PLSE) Risk Channels and Responsive Allocation - Stock Traders Daily
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued? - finance.yahoo.com
PLSE Virtual Meeting on Strategic Initiatives Highlights Growth Expectations Despite High Valuation - GuruFocus
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year HighTime to Buy? - MarketBeat
Pulse Biosciences stock reaches all-time high at 46.03 USD - Investing.com
Pulse Biosciences at Canaccord Genuity conference: nsPFA push gains pace By Investing.com - Investing.com Canada
PLSE: nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption - TradingView
PLSE to Join BTIG Virtual Meeting Amid Elevated Price-to-Sales V - GuruFocus
PLSE Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Pulse Biosciences (NASDAQ:PLSE) Stock Price - MarketBeat
Canaccord raises Pulse Biosciences stock price target on clinical progress - Investing.com India
Canaccord raises Pulse Biosciences stock price target on clinical progress By Investing.com - Investing.com Canada
Weekly Recap: Q2 losses, ATM raises and NANOPULSE-AF study past halfway - TradingView
Pulse Biosciences (PLSE) After NANOPULSE AF Progress As Valuation Questions Build - Sahm
Pulse Biosciences (NASDAQ:PLSE) Announces Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pulse Biosciences (NASDAQ:PLSE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Q2 2026 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - uk.finance.yahoo.com
Sector Update: Healthcare - Moomoo
Pulse Biosciences Shares Rise After Q2 Results - marketscreener.com
Pulse Biosciences (NASDAQ:PLSE) Trading Up 15.7%Should You Buy? - MarketBeat
Pulse Biosciences enters $75 million equity distribution agreement with Mizuho - Investing.com Australia
Pulse Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pulse Biosciences (PLSE) Accelerates Clinical Enrollment, Market Pricing Reflects High Growth Expectations - GuruFocus
Form 8K Pulse Biosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Earnings call transcript: Pulse Biosciences misses Q2 2026 estimates but gains on trial progress - Investing.com Nigeria
Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: - GuruFocus
Did Pulse Biosciences (PLSE) Miss Revenue Estimates Despite Cash Influx? GF Score: 31/100 - GuruFocus
Pulse Biosciences Q2 Earnings Call Highlights - TradingView
Pulse Biosciences Q2 2026 Earnings Call Transcript - MarketBeat
Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: Accelerated Enrollment and ... - Yahoo Finance
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Pulse Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pulse Biosciences earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q2 Revenue $0.4M, vs. FactSet Est of $533K - marketscreener.com
PULSE BIOSCIENCES, INC. 2026: Revenue $434K, EPS ($0.36) — 10-Q Summary - TradingView
Pulse Biosciences posts Q2 2026 loss, $0.4M revenue and $101.6M cash - TradingView
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results - Business Wire
Pulse Biosciences earnings on deck as PFA technology faces test By Investing.com - Investing.com Nigeria
Pulse Biosciences earnings on deck as PFA technology faces test - Investing.com
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
5.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):